Keyword: Saxenda

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Novo Nordisk is hooking up with new-wave weight loss program Noom to support people with obesity.

Samsung BioLogics faces potential delisting; Merck will increase Gardasil supply to China; Chinese officials mulls new regulation for vaccine.

Novo said it cracked down on the wholesaler through its local distributor Zuellig Pharma Korea, which terminated the alleged smuggler’s contract.

Novo Nordisk is about to take on a task that’s so far foiled its peers: expanding the global obesity market.

Still dealing with intense pricing pressure in its key diabetes business, Novo Nordisk is embarking on its latest wave of job cuts.

Novo Nordisk is counting on multiple new drug launches—including the blockbuster-to-be semaglutide to help overcome market headwinds.

Novo has filed a citizen petition saying Victoza’s manufacturing is so complex that equivalence of generics can't be certain without clinical trials.

Novo Nordisk is revving up for a push into Latin America with obesity drug Saxenda, hoping to put sales into a higher gear.